DEPARTMENT OF HEALTH AND HUMAN SERVICES 
NATIONAL INSTITUTES OF HEALTH 
RECOMBINANT DNA ADVISORY COMMITTEE 
MINUTES OF MEETING 1 
September 12-13„ 1994 
The Recombinant DNA Advisory Committee (RAC) was convened for its fifty-ninth 
meeting at 9:00 a.m. on September 12, 1994, at the National Institutes of Health, Building 
31, Conference Room 6, 9000 Rockville Pike, Bethesda, Maryland 20892. Dr. LeRoy B. 
Walters (Chair) presided. In accordance with Public Law 92-463, the meeting was open to 
the public on September. 12 from 9 a.m. until 5 p.m. and September 13 from 8:30 a.m. 
until 3:30 p.m. In accordance with Section 552 b(c)(4), Title 5, U.S.C. and Section 10(d) 
of Public Law 92-463, the meeting was closed to the public on September 12 from 5-5:30 
p.m. to review, discuss, and evaluate proprietary information. The following were present 
for all or part of the meeting: 
Committee Members: 
Alexander M. Capron, University of Southern California 
Gary A. Chase, Georgetown University Medical Center 
Patricia A. DeLeon, University of Delaware 
Roy H. Doi, University of California, Davis 
Krishna R. Dronamraju, The Foundation of Human Genetics 
Robert P. Erickson, University of Arizona 
David Ginsburg, University of Michigan 
Abbey S. Meyers, National Organization for Rare Disorders 
A. Dusty Miller, Fred Hutchinson Cancer Research Center 
Arno G. Motulsky, University of Washington 
Robertson Parkman, Children’s Hospital of Los Angeles 
Gail S. Ross, Cornell University Medical Center 
Bratin K. Saha, Emory University 
R. Jude Samulski, University of North Carolina 
Marian G. Secundy, Howard University College of Medicine 
Brian R. Smith, Yale University School of Medicine 
Stephen E. Straus, National Institutes of Health 
LeRoy B. Walters, Kennedy Institute of Ethics, Georgetown University 
Doris T. Zallen, Virginia Polytechnic Institute & State University 
Executive Secretary: 
Nelson A. Wivel, National Institutes of Health 
A committee roster is attached (Attachment I). 
*The RAC is advisory to the National Institutes of Health (NIH), and its 
recommendations should not be considered as final or accepted. The Office of 
Recombinant DNA Activities should be consulted for NIH policy on specific issues. 
Recombinant DNA Research, Volume 20 [11] 
